HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

California Green Chemistry Reg Revision Narrows “Concern” List

This article was originally published in The Rose Sheet

Executive Summary

California’s latest iteration of the Safer Consumer Products regulations cuts the universe of “chemicals of concern” from 4,000 down to 1,200. The state’s Department of Toxic Substances Control will select the first five chemical/product category combinations up for review 180 days after the regulation enters into force.

You may also be interested in...



California Refines Consumer Products Regs, Exempting Trace Contaminants

California’s Department of Toxic Substances Control has released the next draft of its Safer Consumer Products Regulations, taking into consideration comments from stakeholders.

Cosmetic User Fees, FDA Warnings, California: Top “Rose Sheet” Topics Of 2012

“The Rose Sheet” offers an overview of the year in cosmetics, analyzing 2012’s biggest news and the publication’s most-read stories. Highlights include a proposal in Obama’s 2013 budget request to institute cosmetics user fees, the rash of late-year warning letters and regulatory developments in California.

Industry Pushes For OTC Exemption In California’s Green Regs

The Personal Care Products Council and the Consumer Healthcare Products Association call for the California Department of Toxic Substances Control to specifically exclude OTC drugs from its Safer Consumer Products regulation, part of the state’s Green Chemistry Initiative. Including OTC drugs in the regulation would duplicate oversight and “run counter to the mandates of [FDA],” the groups argue.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018216

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel